FDA Approves Gleevec to Prevent Recurrence of Rare Gastrointestinal Cancer
The U.S. Food and Drug Administration today approved Gleevec (imatinib mesylate) for a new indication keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.